FATE Relative Valuation
FATE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, FATE is overvalued; if below, it's undervalued.
Historical Valuation
Fate Therapeutics Inc (FATE) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -10.47. The fair price of Fate Therapeutics Inc (FATE) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：1.09
Fair
-0.97
PE
1Y
3Y
5Y
Trailing
Forward
0.08
EV/EBITDA
Fate Therapeutics Inc. (FATE) has a current EV/EBITDA of 0.08. The 5-year average EV/EBITDA is -7.68. The thresholds are as follows: Strongly Undervalued below -31.32, Undervalued between -31.32 and -19.50, Fairly Valued between 4.14 and -19.50, Overvalued between 4.14 and 15.96, and Strongly Overvalued above 15.96. The current Forward EV/EBITDA of 0.08 falls within the Historic Trend Line -Fairly Valued range.
0.08
EV/EBIT
Fate Therapeutics Inc. (FATE) has a current EV/EBIT of 0.08. The 5-year average EV/EBIT is -8.49. The thresholds are as follows: Strongly Undervalued below -34.88, Undervalued between -34.88 and -21.68, Fairly Valued between 4.71 and -21.68, Overvalued between 4.71 and 17.90, and Strongly Overvalued above 17.90. The current Forward EV/EBIT of 0.08 falls within the Historic Trend Line -Fairly Valued range.
32.52
PS
Fate Therapeutics Inc. (FATE) has a current PS of 32.52. The 5-year average PS is 78.01. The thresholds are as follows: Strongly Undervalued below -64.49, Undervalued between -64.49 and 6.76, Fairly Valued between 149.27 and 6.76, Overvalued between 149.27 and 220.52, and Strongly Overvalued above 220.52. The current Forward PS of 32.52 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Fate Therapeutics Inc. (FATE) has a current P/OCF of 0.00. The 5-year average P/OCF is -12.91. The thresholds are as follows: Strongly Undervalued below -48.83, Undervalued between -48.83 and -30.87, Fairly Valued between 5.05 and -30.87, Overvalued between 5.05 and 23.01, and Strongly Overvalued above 23.01. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-1.37
P/FCF
Fate Therapeutics Inc. (FATE) has a current P/FCF of -1.37. The 5-year average P/FCF is -13.79. The thresholds are as follows: Strongly Undervalued below -50.54, Undervalued between -50.54 and -32.17, Fairly Valued between 4.59 and -32.17, Overvalued between 4.59 and 22.97, and Strongly Overvalued above 22.97. The current Forward P/FCF of -1.37 falls within the Historic Trend Line -Fairly Valued range.
Fate Therapeutics Inc (FATE) has a current Price-to-Book (P/B) ratio of 0.53. Compared to its 3-year average P/B ratio of 0.91 , the current P/B ratio is approximately -41.35% higher. Relative to its 5-year average P/B ratio of 4.12, the current P/B ratio is about -87.07% higher. Fate Therapeutics Inc (FATE) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -61.38%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -38.78% , the current FCF yield is about -100.00% lower.
0.54
P/B
Median3y
0.91
Median5y
4.12
-92.65
FCF Yield
Median3y
-61.38
Median5y
-38.78
Competitors Valuation Multiple
The average P/S ratio for FATE's competitors is 0.00, providing a benchmark for relative valuation. Fate Therapeutics Inc Corp (FATE) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -43.36%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of FATE decreased by 33.33% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -1.55K to -1.85K.
The secondary factor is the P/E Change, contributed -9.40%to the performance.
Overall, the performance of FATE in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Fate Therapeutics Inc (FATE) currently overvalued or undervalued?
What is Fate Therapeutics Inc (FATE) fair value?
How does FATE's valuation metrics compare to the industry average?
What is the current P/B ratio for Fate Therapeutics Inc (FATE) as of Dec 05 2025?
What is the current FCF Yield for Fate Therapeutics Inc (FATE) as of Dec 05 2025?
What is the current Forward P/E ratio for Fate Therapeutics Inc (FATE) as of Dec 05 2025?